Corcept Therapeutics Incorporated Dividend History (CORT)
Corcept Therapeutics Incorporated does not pay dividends currently 😔
They might in the future, check back soon!
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company founded in 1998, focused on the development of drugs that modulate the effects of cortisol, a hormone involved in various health disorders. The company is particularly noted for its efforts in treating conditions such as Cushing's syndrome and other metabolic, oncologic, and psychiatric disorders. Corcept's flagship product, Korlym, is approved for controlling hyperglycemia in patients with Cushing's syndrome. As of the latest updates, the company's CEO is Joseph K. Belanoff, who also co-founded the company. Corcept is headquartered in Menlo Park, California. In terms of financial performance, the company reported increasing revenues over recent years, reflecting its expanding role in the pharmaceutical industry. Corcept continues to focus on research and development to discover and commercialize innovative therapies that address unmet medical needs.
Annovis Bio, Inc.
Corcept Therapeutics shares soared 6.5% due to strong demand for its drug Korlym and the expected filing of a new drug application for its lead candidate relacorilant. The company's earnings and revenue growth expectations also contribute to the share price rally.
Benzinga · Published on Thu Sep 19 2024
Corcept Therapeutics' (CORT) shares have gained over 45% in the past six months, driven by strong performance of its sole-marketed drug Korlym and progress in the development of its lead pipeline candidate relacorilant for treating Cushing's syndrome.
Benzinga · Published on Tue Sep 03 2024
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeutics.
Zacks Investment Research · Published on Tue Aug 06 2024